Arq Inc Dossier - Source-backed chat

Arq Inc

ARQNASDAQ

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)2.24

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.98Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $86.2M

Enterprise Value $116M

Shares Outstanding 42M diluted

Next Earnings Date4 Nov 2026

Last ex-dividend20 Feb 2020

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arq, Inc. (ARQ) represents a compelling turnaround and environmental technology play. While the company has faced severe execution challenges and delays in its Granular Activated Carbon (GAC) expansion—culminating in a temporary pause of GAC production for 2026—the core Powdered Activated Carbon (PAC) business remains highly robust and profitable. Trading at a significant discount following the GAC-related selloff, the risk/reward ratio is highly attractive. The upcoming strategic optimization review in Q3 2026 and the appointment of a highly experienced CFO (Shimon Steinmetz) provide clear catalysts for regaining investor confidence.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.88

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

The GAC strategic review reveals that restarting production requires prohibitive capital expenditures, leading to a permanent write-down of the $100 million investment. Core PAC operations face unexpected pricing pressure or operational disruptions, causing the company to miss its 2026 guidance. Tightening covenants under the MidCap Financial facility force dilutive equity financing.

Base CaseCentral scenario

$5.7560%

The core PAC business continues its steady operating momentum, meeting the reaffirmed 2026 revenue guidance of $120 million to $125 million and Adjusted EBITDA of $17 million to $20 million. The GAC strategic review in Q3 2026 establishes a realistic, phased timeline with clear funding sources, stabilizing investor sentiment. The stock rerates toward historical multiples as execution risks subside under the new CFO.

Bull CaseUpside scenario

$8.0025%

The strategic optimization review outlines a highly profitable, low-capex joint venture or partnership model to fund and complete the GAC expansion. Core PAC demand surges due to tightening environmental regulations, driving ASPs above $0.91 per pound. The company achieves the high end of its 2026 Adjusted EBITDA guidance ($20 million) and successfully restarts GAC production in early 2027, capturing a massive share of the PFAS water treatment market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong operating momentum in the core PAC business, which is expected to generate $120M-$125M in revenue and $17M-$20M in Adjusted EBITDA in 2026.
Highly attractive valuation following the GAC-related selloff, with the stock trading at an enterprise value that undervalues the core PAC cash flows.
Favorable long-term regulatory tailwinds, including the EPA's strict PFAS drinking water standards driving massive future demand for activated carbon.
Strong alignment of interest, with the Board and management team collectively owning more than 20% of the outstanding common stock.

Key Investment Risks

Extended delays and capital overruns in the GAC expansion project, which has already seen over $100 million in investment paused.
Tight liquidity and covenant constraints under the MidCap Financial credit facility, potentially requiring dilutive financing.
Leadership transition risks following the resignation of the Chief Accounting Officer and the upcoming onboarding of the new CFO.

Thesis Invalidation Triggers

A formal decision in the Q3 2026 strategic review to permanently abandon the GAC market with no capital recovery.
A breach of financial covenants under the MidCap Financial credit facility leading to an acceleration of debt.
A material downward revision of the full-year 2026 revenue or Adjusted EBITDA guidance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.